首页|氯诺昔康、骨肽等药物在治疗骨性关节炎中的临床观察

氯诺昔康、骨肽等药物在治疗骨性关节炎中的临床观察

扫码查看
目的 探讨氯诺昔康、骨肽等药物联合使用对骨性关节炎的治疗效果.方法 选取本院2014年5月~2016年6月期间收治的260例骨性关节炎患者,经单双数字法随机均分为研究组和对照组,每组130例.对照组患者炎给予透明质酸钠联合氯诺昔康治疗,研究组在对照组治疗基础上加用骨肽.观察比较2组患者的疼痛评分,膝关节功能和不良反应情况.结果 治疗前,2组VAS、WOMAC量表评分差异无统计学意义;治疗后,研究组VAS、WOMAC量表评分改善效果优于对照组(P<0.05);2组患者药物相关不良反应发生率比较差异无统计学意义.结论 透明质酸钠、骨肽、氯诺昔康等药物联合治疗骨性关节炎患者临床疗效明显,且不良反应较少.
Lornoxicam,clinical observation and peptide drugs in the treatment of osteoarthritis
Objective To investigate the combined use of osteoarthritis treatment effect of lornoxicam and peptide drugs.Methods 260 patients with osteoarthritis treated in our hospital from May 2014 to June 2016 were selected, were randomly divided into study group and control group, each group of 130 cases.The patients in the control group were treated with sodium hyaluronate and lornoxicam, the study group was given bone peptide on the basis of the control group. The pain scores, knee function and adverse reactions were compared between the two groups.Results There was no significant difference in VAS and WOMAC scores between the two groups before treatment; after treatment, the improvement of VAS and WOMAC score in the study group was better than that in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion Sodium hyaluronate, bone peptide, lornoxicam and other drugs in the treatment of patients with osteoarthritis clinical efficacy is obvious, and fewer adverse reactions.

osteoarthritispeptidelornoxicamcombination therapytherapeutic effect

高龙、陈英、刘环、杨昭、张虎虎

展开 >

西安市高陵区医院 疼痛科,陕西 西安 710200

骨性关节炎 骨肽 氯诺昔康 联合用药 治疗效果

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(9)
  • 2
  • 7